ArticleEinstein (Sao Paulo, Brazil)2026
Insights from long-term follow-up of patients treated with oral immunotherapy for cow's milk allergy.
Article in Einstein (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe the long-term outcomes of patients undergoing oral immunotherapy for cow's milk allergy in a pediatric allergy clinic, focusing on treatment efficacy and adverse reactions over 5 years of follow-up.
methodsThis retrospective cohort study reviewed medical records of patients aged 5-18 years who underwent cow's milk oral immunotherapy at Instituto da Criança, São Paulo. All patients initiated treatment between 2013 and 2019 and completed at least 5 years of maintenance follow-up. Evaluated outcomes included treatment adherence, adverse reactions, anaphylaxis, and eosinophilic esophagitis. Data were analyzed descriptively, and statistical tests were applied.
resultsThirty patients entered the maintenance phase (median age, 8.2 years). Most had allergic comorbidities and a history of anaphylaxis. Four patients discontinued treatment within the first trimester: two due to anaphylaxis and two due to eosinophilic esophagitis. Adverse reactions were predominantly mild and decreased significantly over time (p=0.01). Severe reactions accounted for 17% of events, including 22 episodes of anaphylaxis. Eosinophilic esophagitis was diagnosed in 33% of patients and occurred more frequently among those initiating treatment after 12 years of age.
conclusionLong-term oral immunotherapy increased tolerance and enabled regular milk ingestion in most patients. Older age at treatment initiation was associated with a higher incidence of eosinophilic esophagitis. Careful patient selection and structured monitoring during and after treatment are essential for early identification of severe reactions and eosinophilic esophagitis. Larger studies with longer follow-up are needed to optimize protocols and improve safety strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.